ArticleInternational journal of clinical and experimental pathology2019
H3K27 trimethylation and H3K9 dimethylation as poor prognostic markers for patients with esophageal squamous cell carcinoma.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Advances in epigenetic therapy for esophageal cancer.Clinical epigenetics · 2026Review
- Targeting epigenetic deregulations for the management of esophageal carcinoma: recent advances and emerging approaches.Cell biology and toxicology · 2023Review
- H3K27me3 Inactivates SFRP1 to Promote Cell Proliferation via Wnt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma.Digestive diseases and sciences · 2023Article
- DNA-methylation and genomic copy number in primary tumors and corresponding lymph node metastases in prostate cancer from patients with low and high Gleason score.Clinical and translational radiation oncology · 2023Article
- Review
- Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma.The Journal of international medical research · 2021Article
- Clinicopathologic significance of protein lysine methyltransferases in cancer.Clinical epigenetics · 2020Review
- Luminescent Coordination Polymer for Picric Acid Detection and Treatment on Spinal Cord Injury Model Via Upregulating the trka Expression.Journal of fluorescence · 2020Article
- LINC00673 Represses CDKN2C and Promotes the Proliferation of Esophageal Squamous Cell Carcinoma Cells by EZH2-Mediated H3K27 Trimethylation.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer (EC) is the fourth most commonly diagnosed cancer in males and the fifth in females in China. Dysregulation methylation of histone is now considered a biomarker for cancer prognosis.
methodsIn this study, we focused on exploring the expression patterns of two repressor histone methylation marks, H3K9 dimethylation (H3K9me2) and H3K27 trimethylation (H3K27me3), to provide potential biomarkers for diagnosis and therapies in esophageal squamous cell carcinoma (ESCC).
resultsAfter analyzing the relationship between the expression pattern of H3K27me3 and the clinic-pathological features of ESCC tissues, we found that upregulated H3K27me3 correlated with advanced T stage and N stage. A multivariate Cox regression analysis showed H3K27me3 expression, T stage and N stage were all independent factors for the poor prognosis of ESCC. Therefore, H3K27me3 can be considered an independent factor for predicting the prognosis of ESCC.
conclusionsChromatin remodeling, especially the methylation of H3, plays a vital role in ESCC development and is a potential therapeutic target.
Indexed as
Identifiers
31934095PMC6949571W3005166738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.